US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWVphYlZWc0RER3F3c09sMXhsQkE4b0lzaXhWM3FYV2lza19mU3Y1WWI4WElZbmxOc3FGUE9UaUN2VmVQYjRuaHJQU0lQS3V5Y2Z5Wk1lVkNGelEyMHMwSXR1YWRWYk9ULV9zTFBvX291RmpHakpodm04MHpfWl9lZlVhVGdiM2tiQ3BWb080NWFrR1VUdUxsb2FmTE5LT2xnSlZrVHotRzY3OHV0d0d2djlUSUVEV3lQeXY5VnBvWWlHUTZZNXd1Yw?oc=5" target="_blank">US FDA approves Axsome's drug for Alzheimer's-related agitation</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

The FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for treating agitation in Alzheimer's patients, marking the first non-antipsychotic treatment for this condition.

Axsome Therapeutics announced the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.

The FDA approved Axsome Therapeutics' drug, Auvelity, to treat agitation in Alzheimer's patients, offering an alternative to antipsychotic drugs.

Axsome Therapeutics received FDA approval for Auvelity to treat Alzheimer's disease agitation, accessing a $1 billion-plus market and offering a clean label compared to competitors.

The FDA approved Axsome Therapeutics' Auvelity for treating agitation in Alzheimer's disease, providing a new option to ease caregiver burden.